Our monthly newsletter reports on the patent law developments in biotech, biologics and pharmaceutical cases, legislation and federal agency actions. This month’s issue covers relevant news from January 2020, including:
- The Federal Circuit holds that post-priority evidence can be used to show inherency in the obviousness context
- The Federal Circuit explains that enablement of an allegedly anticipatory reference does not necessarily equate to anticipation and the two concepts should not be confused
- A district court holds, in a drug/prodrug case, that the enforceable rights derived from a patent term extension are limited to the approved uses of the approved active ingredient
